This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Implied Volatility Surging for Seres Therapeutics (MCRB) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Seres Therapeutics (MCRB) stock based on the movements in the options market lately.
MCRBPositive Net Change
biotechs
3 Biotech Stocks Poised to Gain in the Second Half of 2021
by Ekta Bagri
Here we present three biotech companies, which outperformed the sector in the year so far and are likely to witness a winning run in the near term.
REGNNegative Net Change BIIBNegative Net Change AMGNPositive Net Change MRNANegative Net Change RGENNegative Net Change NTLANegative Net Change BNTXNegative Net Change
biotechs pharmaceuticals
Gilead (GILD) Gains 19% YTD: What to Expect in The Second Half?
by Zacks Equity Research
Gilead (GILD) maintains momentum in the year so far on the back of Veklury for the treatment of COVID-19 and the same is expected to continue in the second half.
NVONegative Net Change MRKNegative Net Change GILDNegative Net Change JNCEPositive Net Change
biotechs medical
Alector (ALEC) Up on Tie-Up With Glaxo for Neurological Diseases
by Zacks Equity Research
Alector (ALEC) signs a global collaboration deal with Glaxo to co-develop/commercialize two monoclonal antibodies - AL001 and AL101 ¿¿¿ for treating various neurodegenerative diseases. Stock up.
GSKNegative Net Change RGENNegative Net Change TRVNNo Net Change ALECNegative Net Change
biotechs
Glaxo (GSK)/Alector Ink Deal for Neurodegenerative Indications
by Zacks Equity Research
Glaxo (GSK) and Alector set to co-develop and co-commercialize AL001 and AL101 for neurodegenerative diseases. Glaxo issues a formal response to activist hedge investor, Elliott's call for board changes.
GSKNegative Net Change BAYRYNegative Net Change ALECNegative Net Change
biotechs pharmaceuticals
Moderna ETFs to Rise on Positive COVID-19 Vaccine Updates
by Sweta Jaiswal, FRM
Moderna has once again come up with interesting updates about its COVID-19 vaccine.
AZNNegative Net Change PFENegative Net Change MRNANegative Net Change IBBNegative Net Change BBHNegative Net Change IDNANegative Net Change
biotechs etfs
3 Reasons to Invest in Regeneron Pharmaceuticals (REGN) Now
by Zacks Equity Research
Regeneron's (REGN) efforts to expand the label of its approved drugs and concurrently develop the pipeline are impressive and makes it a good bet for investors, for now.
REGNNegative Net Change SNYNegative Net Change RHHBYNegative Net Change BAYRYNegative Net Change
biotechs pharmaceuticals
Arcutis (ARQT) Terminates Study of Drug to Treat Vitiligo
by Zacks Equity Research
Arcutis (ARQT) ends phase IIa study evaluating its investigational anti-JAK1 candidate, ARQ-252, to treat vitiligo.
BAYRYNegative Net Change RGENNegative Net Change BNTXNegative Net Change ARQTNegative Net Change
biotechs
Apellis (APLS) Up on Tie-up With Beam for Novel Therapies
by Zacks Equity Research
Apellis (APLS) signs a collaboration deal with Beam Therapeutics to develop new treatments for complement-driven diseases. Shares rise.
BEAMNegative Net Change RGENNegative Net Change TRVNNo Net Change APLSPositive Net Change
biotechs
Oncology Space Gains Momentum in 2021: 5 Stocks to Focus on
by Debanjana Dey
Oncology stocks like OncoCyte (OCX), PerkinElmer (PKI), Catalent (CTLT), Cardiff Oncology (CRDF) and NovoCure (NVCR) are expected to continue their run over the next few months.
NVSNegative Net Change PKIPositive Net Change CTLTPositive Net Change NVCRNegative Net Change CRDFNegative Net Change
biotechs medical
Allogene (ALLO) Multiple Myeloma Candidate Gets Fast Track Tag
by Zacks Equity Research
Allogene's (ALLO) next-generation allogeneic CAR T therapy, ALLO-605, gets Fast Track designation from the FDA to treat patients with relapsed or refractory multiple myeloma.
BAYRYNegative Net Change CLLSNegative Net Change ALLOPositive Net Change BNTXNegative Net Change
biotechs
Deciphera (DCPH) Begins Dosing in Study on Cancer Candidate
by Zacks Equity Research
Deciphera (DCPH) doses the first patient in a phase I study evaluating its ULK kinase inhibitor, DCC-3116, for treating advanced/metastatic tumors driven by mutations in RAS/RAF genes.
NVSNegative Net Change PFENegative Net Change RGENNegative Net Change DCPHPositive Net Change
biotechs
Biotech Stock Roundup: NTLA Surges on Study Data, EXEL & ALT Down on Updates & More
by Zacks Equity Research
The biotech sector was in focus last week with pipeline updates from Intellia (NTLA), Exelixis (EXEL) and Regeneron (RGEN), among others.
REGNNegative Net Change SNYNegative Net Change BMYNegative Net Change MRNANegative Net Change EXELPositive Net Change ALTNegative Net Change NTLANegative Net Change
biotechs pharmaceuticals
Horizon (HZNP) Begins Phase II Study for Lupus Candidate
by Zacks Equity Research
Horizon (HZNP) starts phase II study to evaluate HZN-7734, an antibody to treat systemic lupus, which is an autoimmune disease wherein the immune system mistakenly attacks healthy cells and tissues.
BAYRYNegative Net Change HZNPPositive Net Change RGENNegative Net Change BNTXNegative Net Change
biotechs
Moderna (MRNA) COVID-19 Vaccine Effective Against Delta Variant
by Zacks Equity Research
Moderna's (MRNA) share price reaches all-time high, following authorization from the government of India for mRNA-1273 and encouraging neutralizing activity against several COVID-19 variants demonstrated in studies.
PFENegative Net Change MRNANegative Net Change CTLTPositive Net Change BNTXNegative Net Change
biotechs
Cerevel (CERE) Novel Schizophrenia Drug Succeeds in Phase I
by Zacks Equity Research
Cerevel Therapeutics (CERE) surges as schizophrenia candidate, CVL-231, demonstrates clinically meaningful and statistically significant improvement in PANSS Total score at 6 weeks in phase Ia study.
PFENegative Net Change CEREPositive Net Change NERVPositive Net Change
biotechs
Iovance (IOVA) Announces Lung Cancer Study Data on TIL Therapy
by Zacks Equity Research
Iovance (IOVA) is developing several TIL therapies, including LN-145, in a mid-stage study. Data from the lung cancer cohort evaluating LN-145 monotherapy demonstrates an ORR of 21.4%.
BMYNegative Net Change MRKNegative Net Change IOVAPositive Net Change BNTXNegative Net Change
biotechs
The Zacks Analyst Blog Highlights: Intellia Therapeutics, Regeneron Pharmaceuticals, CRISPR Therapeutics, Beam Therapeutics and Vertex Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Intellia Therapeutics, Regeneron Pharmaceuticals, CRISPR Therapeutics, Beam Therapeutics and Vertex Pharmaceuticals
REGNNegative Net Change VRTXNegative Net Change BEAMNegative Net Change NTLANegative Net Change CRSPNegative Net Change
biotechs medical
Gilead's (GILD) Kite Announces Positive Data on Yescarta
by Zacks Equity Research
Gilead (GILD) announces results from the ZUMA-7 study on Yescarta and completes submission of application to the FDA seeking approval of lenacapavir.
NVSNegative Net Change BMYNegative Net Change GILDNegative Net Change ALLOPositive Net Change
biotechs medical pharmaceuticals
Exelixis (EXEL) Down on Data from Ongoing Liver Cancer Study
by Zacks Equity Research
Exelixis (EXEL) and partner announce unimpressive data from the late-stage COSMIC-312 study in patients with previously untreated advanced hepatocellular carcinoma.
RHHBYNegative Net Change BMYNegative Net Change EXELPositive Net Change RGENNegative Net Change
biotechs pharmaceuticals
Intellia (NTLA) Up on Positive Gene-Editing Drug Interim Data
by Zacks Equity Research
Intellia (NTLA) posts positive interim data from phase I study on lead genome-editing candidate NTLA-2001 being developed for treating transthyretin (ATTR) amyloidosis. Stock up.
REGNNegative Net Change EDITPositive Net Change NTLANegative Net Change CRSPNegative Net Change
biotechs
BioMarin (BMRN) Re-Files MAA for Hemophilia Gene Therapy in EU
by Zacks Equity Research
Biomarin Pharmaceutical's (BMRN) new MAA in EU includes 52 weeks' data from the phase III GENEr8-1 study, along with four and three-year follow-up data from the ongoing phase I/II dose escalation study.
RHHBYNegative Net Change PFENegative Net Change BMRNNegative Net Change SGMOPositive Net Change
biotechs
3 Biotech Stocks Up on Intellia's CRISPR Therapy Study Data
by Zacks Equity Research
Intellia (NTLA) announces first-ever, promising clinical data on an in vivo CRISPR-based therapy. Stocks of CRSP, EDIT and BEAM rise on investor enthusiasm about their CRISPR-based candidates.
REGNNegative Net Change VRTXNegative Net Change BEAMNegative Net Change EDITPositive Net Change NTLANegative Net Change CRSPNegative Net Change
biotechs
Company News for Jun 29, 2021
by Zacks Equity Research
Companies in the news are: NTLA, AVXL, MNKD, KYMR
MNKDNegative Net Change AVXLNegative Net Change NTLANegative Net Change KYMRNegative Net Change
biotechs medical pharmaceuticals
Bristol Myers (BMY) Gets Positive CHMP Opinion for Abecma
by Zacks Equity Research
Bristol Myers (BMY) obtains positive CHMP opinion for cell immunotherapy, Abecma, for multiple myeloma and Opdivo for the indication of gastroesophageal junction cancer.
BMYNegative Net Change MRKNegative Net Change RGENNegative Net Change
biotechs pharmaceuticals